Nonacog beta pegol clinical trials
How each study uses nonacog beta pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 31 May 2017 · Rebinyn · BLA 125611 (FDA, Purple Book)
- European Union
- 2 Jun 2017 · Refixia · EMEA/H/C/004178 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses nonacog beta pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia BCompletedPhase 3Novo Nordisk A/SNCT05365217Written as Nonacog beta pegol
- Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia BCompletedPhase 3Novo Nordisk A/SNCT02141074Written as nonacog beta pegol
- Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.CompletedPhase 3Novo Nordisk A/SNCT01467427Written as nonacog beta pegol
- A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia BCompletedPhase 1Novo Nordisk A/SNCT03075670Written as N9-GP
- Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773CompletedPhase 3Novo Nordisk A/SNCT01395810Written as nonacog beta pegol
- Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia BCompletedPhase 3Novo Nordisk A/SNCT01386528Written as nonacog beta pegol
- Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B PatientsCompletedPhase 3Novo Nordisk A/SNCT01333111Written as nonacog beta pegol
- Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia BCompletedPhase 1Novo Nordisk A/SNCT00956345Written as nonacog beta pegol
Codes
What other systems call nonacog beta pegol · ClinicalTrials.gg INT000088
- MeSH (NLM) C000592276nonacog beta pegolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 27Y83O992QNONACOG BETA PEGOLConfirmed FDA, NLM, Wikidata
- RxNorm 1990855Confirmed FDA, Wikidata
- Wikidata Q109979623nonacog beta pegolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166552Nonacog Beta PegolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592276 | nonacog beta pegol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 27Y83O992Q | NONACOG BETA PEGOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1990855 | — | Confirmed FDA, Wikidata |
| Wikidata | Q109979623 | nonacog beta pegol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166552 | Nonacog Beta Pegol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.